The figure outlines the two major, novel concepts of this paper. Starting from the established favorable prognostic value of MRD negativity on PFS (top central panel showing PFS Kaplan-Meier curves for intention-to-treat patients pooled from both studies; in purple are patients who achieved MRD⁻ status at any point during the study; in yellow are patients who were MRD⁺). The authors showed (1) sustained MRD negativity over 12 months is a stronger favorable prognostic factor (left lower graph depicting Kaplan-Meier curves for PFS for intention-to-treat patients pooled from both studies; purple lines represent patients who were MRD⁻ at 1 point during the course of the studies [dotted] or sustained over the course of 12 months [solid]. The yellow line represents patients who were MRD⁺); and (2) Dara improves PFS regardless of MRD status (right lower graph depicting Kaplan-Meier curves for PFS for intention-to-treat patients pooled from both studies; purple lines represent patients who were treated with Dara; yellow lines represent patients who received no Dara; solid lines represent MRD⁻ patients; and dotted lines represent MRD⁺ patients at any point during the course of the trials). CI, confidence interval; HR, hazard ratio.